|
Mesothelioma
Treatment
Abstracts
& Articles
Systemic
drug therapy of malignant pleural
mesothelioma.
Monaldi
Arch Chest Dis 1998
Apr;53(2):236-40
Ardizzoni
A, Grossi F, Pennucci MC
Istituto
Nazionale per la Ricerca sul Cancro,
Division of Medical Oncology I, Genova,
Italy.
Malignant
pleural mesothelioma (MPM) is an uncommon
malignancy characterized by a rapid
clinical course. Few patients are possible
candidates for radical surgery. According
to most reviews, radiotherapy has a
limited role in the treatment of MPM. The
role of chemotherapy in the management of
pleural mesothelioma still remains
uncertain. The available data indicate
that although 10-20% of patients are known
to achieve on objective response to a
number of chemotherapeutic agents, the
impact on survival appears limited and
improvement in the quality of life remains
uncertain. The results of combination
chemotherapy are comparable to those of
single-agent chemotherapy and no major
difference is detectable among the various
combinations. Prospective phase II trials
are recommended for the identification of
new active treatments while large-scale
randomized phase III trials are needed to
identify the best available treatment. In
addition, new standard criteria for
eligibility and response assessment are
required. This paper reviews the available
literature on the systemic drug therapy of
MPM.
PMID:
9689814, UI: 98354239
Click here to order or save
article
If
you have any questions regarding treatment
options or your legal rights, please
contact
us.
|